US Pharm. 2013;38(5):42.
Washington, DC—Manufacturers of generic versions of the painkiller OxyContin will be required to include recent formulation changes designed to make it more difficult to abuse the pill. The FDA will not approve any generic versions that are based on the original formulation, which could be crushed and then snorted or injected. The FDA recently approved updated labeling for the newer, reformulated version of OxyContin, which was designed to be tamper-resistant. The new labeling indicates that the product has physical and chemical properties that are expected to make abuse via injection difficult and to reduce abuse via the intranasal route (snorting). Applications to sell generic versions were based on the older, non–tamper-resistant formulation.
To comment on this article, contact firstname.lastname@example.org.